Two doses of the Pfizer Inc and BioNTech COVID-19 vaccine are extremely protecting in opposition to a uncommon however typically critical situation in kids that causes organ irritation weeks after COVID-19 infections, a U.S. Facilities for Illness Management and Prevention report stated on Friday.
The vaccine was estimated to be 91% efficient in stopping Multisystem Inflammatory Syndrome in Youngsters (MIS-C) in 12- to 18-year-olds, the research stated. MIS-C causes irritation in kids in organs together with the center, lungs, kidneys and mind two to 6 weeks after a gentle or asymptomatic an infection.
The estimate relies on the evaluation of 283 hospitalized sufferers aged 12–18 years at 24 kids's hospitals in 20 states between July and early December, when the prevalence of the Delta coronavirus variant was excessive.
All 38 MIS-C sufferers requiring life assist had been unvaccinated, the research stated.
The outcomes add to a rising physique of proof that vaccination in opposition to COVID-19 is more likely to forestall disease-related issues in kids, together with MIS-C, the report stated. It was not beforehand recognized whether or not the Pfizer/BioNTech vaccine prevented the situation.
The research's findings have a number of limitations together with questions on vaccine effectiveness in opposition to the fast-spreading Omicron variant, the report printed within the CDC's Mortality and Morbidity Weekly Report (MMWR) stated.
Youngsters aged 5–11 years are at highest threat for MIS-C however solely grew to become eligible for the Pfizer-BioNTech vaccine in late October in the US. They weren't included within the evaluation, the report stated.
(Reporting by Manojna Maddipatla in Bengaluru; Enhancing by Cynthia Osterman)
Noah Chen, 13, will get a shot of the Pfizer COVID-19 vaccine on the First Baptist Church of Pasadena, Friday, Could 14, 2021, in Pasadena, Calif. (AP Picture/Marcio Jose Sanchez)
Post a Comment